Technology Search | ipal – Ihr professioneller Vermarkter von Erfindungen / Patenten

Your search found 77 results

Chemerin9 Variants for Diagnosis and Therapy of Pancreatic and Oesophageal Cancer

07.03.2012 | Ref.Nr. 11115

Life Science › Medical Devices › Imaging

Imaging of subcutaneous oesophageal tumors at the flanks of the animals with labeled vChem9 peptide (source: Grötzinger, Bandholz, NP2D 2011).Background
Pancreatic and oesophageal tumors are comparatively rare but characterized by high mortality rates. One reason is that such tumors are commonly detected only at advanced stages of cancerous disease. Often the disease is detected by chance, for instance during the course of other medical examinations.

Technology
Occurrence of CMKLR1, a G protein-coupled receptor, was found to be elevated in oesophageal squamous cell carcinoma and pancreatic adenocarcinoma. We offer peptidic variants of CMKLR1 ligand Chemerin9 with highest stability and optimized ligand binding properties. Attached to a detectable label or therapeutically active agent the peptide variants are suitable for imaging of mestastases formation in pancreatic and oesophageal tumors and its therapy in a theranostic approach.

IP Rights
European priority application filed

Patent Owner
Charité – Universitätsmedizin Berlin

Application Area:

Predictive imaging, Therapy monitoring, Micro-dosing approach

Development Stage: in vivo

Tags: Imaging, micro dosing delivery, theranostics, tumor therapy,

Further Categories: Diagnostics, Life Science, Medical Devices, Imaging

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Suitable Industry: Diagnostics, Biotechnology, Pharmaceuticals

Benefits:

Reliable diagnosis of primary pancreatic and oesophageal tumors
Promising Target: CMKLR1
Reliable detection of early metastases
Suitable for routine medical screening

New Stochastic Method for Sequence Recognition

06.03.2012 | Ref.Nr. 07042

Download as PDF PDF Download Share

Physics&Engineering

Figure: Example for the transformation of a time continual stochastic chain (upper line) in a time discrete stochastic left-right process (lower line) Source: TU Berlin, Kühn, Gühmann Technology

We offer a new stochastic method for sequence recognition, which is suitable for detection of for example speech, text or handwriting recognition. In tests it outperformed Hidden Markov Models (HMM’s) and other approaches significantly, which were state of the art for pattern recognition of sequences up till now.

The new sequence recognition method is nearly under and over fitting free. The training procedure doesn’t require an initial set of parameters or incremental optimization, so that the training can run fully automated. The method is able to do “word spotting” in very long sequences. Because of its unique nature it is very insensitive to non-linear distortion. The needed computing cost is low, thus the new method for sequence recognition can work in real time.

IP Rights
EP and US patent application with priority on July 2007

Patent Owner
Technische Universität Berlin

Application Area:

Voice recognition, Image recognition, Biometry data acquisition, Virus scanner

Development Stage: product

Further Categories: Communication, Algorithms, Video, ICT & Software, Physics & Engineering

Licensing Manager: Jeanne Trommer

T +49 30 2125 4831

F +49 30 2125 4822

jeanne.trommer@ipal.de

Suitable Industry: Automotive, Software, Navigation Technology, Telecommunication, Internet Provider/Services

Benefits:

One step stochastic method for pattern recognition
High recognition rate, low error rate
Unsusceptible to non-linear distortion
Nearly under- and over-fitting free
Low consumption costs, works in real time
Extensions that were developed for HMM’s can be transferred (e.g. adaption methods, connected speech recognition)

Ultra-wet Gas Turbine

01.03.2012 | Ref.Nr. 09139

Download as PDF PDF Download Share

Physics&Engineering

Background
We offer a method to improve the passive scalar homogenization of mixing fluidic jets in cross flow configurations especially within the combustion chamber of a turbine. This is achieved by using fluidic oscillators that create an oscillating or pulsating fluid flow at the oscillator exit due to their way of construction. By this improved method high amounts of steam can be added to the combustion process and thus significantly increase the level of efficiency.

The oscillation frequency of the injected fuel is thereby regulated only by the mass feed of the supplied fluid.
The combination of cross flow injection and oscillation/pulsation of the fluid flow increases primarily the mixing ration of the two fluid flows within a combustion chamber (fluid & air) and moreover leads to a more effective burning.
The fluidic actuators can be installed within new (gas) turbines but can also be integrated in already existing ones.

IP Rights
PCT application filed

Patent Owner
Technische Universität Berlin

Application Area:

The proposed method can be used in all known application fields of (gas) turbines. The fluidics can be installed with new turbines but can also be integrated in already existing systems.

Development Stage: Lab level

Tags: combustion, cross flow, fluid mixture, fluidics, oscillator, turbine,

Further Categories: Energy, Environment engineering, Machine & Plant Technology, Traffic engineering, Physics & Engineering

Licensing Manager: Jeanne Trommer

T +49 30 2125 4831

F +49 30 2125 4822

jeanne.trommer@ipal.de

Benefits:

Better temporal homogenization: NOx reduction, improved fuel value
Pressure loss in turbine is reduced: enhancing performance rate
Decrease of mixing length by ca. 50%: turbines could be build smaller
Fluidic oscillators require less maintenance
Usage of nearly any gaseous fuels
Increased macro- and micromixing phenomena: higher gains in mixing quality

Handling Robot SAMARA

27.02.2012 | Ref.Nr. 05001

Download as PDF PDF Download Share

Physics&Engineering

Scheme of a the SAMARA robotBackground
The handling robot system SAMARA (System Applying Momentum transmission for Acceleration of an end-effector with Redundant Axis) combines the advantages of heavy payloads and wide working space from Scara robots with the high acceleration of Delta robots. This is achieved by a new motion sequence that is characterized by a steadily rotation of the first axis. Thus it is necessary to accelerate only small masses, as the main part of energy used for the motion cycle is kept for the following cycle.

By applying such a redundant axis the kinetic energy can be retained in the robot links during a picking process and returned to the effector for speeding up the whole robot additional to the drives torques. As the nullspace movement ends with a stretched second and third link, acceleration of the effector must be regarded as an impulse, leading to acceleration of 20g.
SAMARA allows solving “pick and place“ tasks even for heavy loads extremely fast, precise and energy-beneficial with only little space required for the SAMARA robot itself.

IP Rights
German Patent Application

Patent Owner
Technische Universität Berlin

Application Area:

Palletizing tasks in food packaging, handling and supplying activities in assembling, alternative to Scara and Delta robots.

Development Stage: prototype

Tags: Automatization, fast acceleration, pick&place, redundant axis, robotics, robots,

Further Categories: Physics & Engineering

Licensing Manager: Jeanne Trommer

T +49 30 2125 4831

F +49 30 2125 4822

jeanne.trommer@ipal.de

Benefits:

Under actuated motion
Highly dynamic operation of multiple arms within same work space
Suitable for heavy payloads
Wide working space
High acceleration (up to 20g)
Only low space required
Flexible and very precise
Combination of various end-effectors possible
Continuous movement reduces energy loss caused by stopping and change of direction

Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases

15.02.2012 | Ref.Nr. 09061

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Biphosphonate with a prolonged carbon chain.Background
Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) - the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases.

Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis.

IP Rights
EP Application (08/2009).
PCT Application (08/2010).
A PCT application was filed in August 2010.

Patent Owner
Humboldt-Universität zu Berlin
Rheinisch-Westfälische
Technische Hochschule Aachen (RWTH)

Application Area:

Drug candidates for the treatment of inflammatory lung diseases, cystic fibrosis and atherosclerosis.

Development Stage: Ex vivo

Tags: Acid Sphingomyelinase, athero-sclerosis, bisphosphonate, cystic fibrosis, inflammatory lung diseases, Inhibitor,

Further Categories: Life Science, Medical Devices, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Pharmaceuticals

Benefits:

Neutral sphingomyelinase is not influenced
First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent
Inhibition of dexamethasone induced apoptosis was proven in vitro
Substances can easily be synthesized in a one-step or two-step procedure
Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate

Porous Metal Oxide Films

06.01.2012 | Ref.Nr. 09068

Download as PDF PDF Download Share

Physics&Engineering

SEM image of a macroporous network (Sokolov, Paul, Krähnert. 2009)Background
Thin porous metal oxide films offer unique physical, electrical and magnetic properties with applications in various fields including catalysis, gas sensing and separation, power storage and generation as well as biology and medicine. Currently known synthesis techniques for metal oxide films with templated porosity (e.g. dip-coating, spin-coating) show significant limitations when they are faced with large substrates and/or substrates with a micro-structured surface.

Technology
We offer an improved method for the production of porous metal oxide films on a substrate using template assisted electrostatic spray deposition (ESD). It overcomes all known problems of current technologies like dip- and spin coating.This novel method is able to produce unisized mesoporous and macroporous films by directly controlling the size and concentration of the pore forming organic templates in an initially formed precursor solution.

IP Rights
PCT Application with priority on October 2009

Patent Owner
Technische Universität Berlin, Germany

PDF Download

Application Area:

Catalysis, Sensors (gas sensors), (Dye sensitized) solar cells, Templates, Displays

Development Stage: Product

Tags: Metal oxide, Pore, Porous,

Further Categories: Catalysis, Physics & Engineering

Licensing Manager: Jeanne Trommer

T +49 30 2125 4831

F +49 30 2125 4822

jeanne.trommer@ipal.de

Suitable Industry: Chemistry, Photovoltaic, Electronic, Optoelectronic

Benefits:

Hierarchically structured meso- and macroporous films
Control of pore morphology (volume, size, distribution, connectivity)
Pores can be coated with catalytic active material
Various substrates can be used
Coating of large substrates
Easy transfer to industrial applications
Production under room conditions

C3bot Peptides as Drugs for the Treatment of Traumatic or Degenerative Neuronal Injury

21.12.2011 | Ref.Nr. 08167

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Figure : Neurocyte Picture: Höltje et al. 2009Background
Peptide fragments of the C3 exoenzyme of Clostridium botulinum have been found to have neuritogenic effects on neurons as well as regenerative proper-ties in an animal model (mouse). The peptides represent promising drug candidates for the treatment of neurodegenerative disorders such as Morbus Alzheimer, Parkinson, Huntington chorea but also for spinal cord injury and traumatic brain injury.enic effects on neurons as well as regenerative properties in an animal model (mouse).

Technology
We offer neuron-specific short peptides for the treatment of neurodegene-rative disorders. Whereas a 26mer peptide stimulates both, dendritic and axonal growth, a 15mer peptide selectively promotes axonal growth. Both, the 15mer and the 26mer peptide trigger a strong transient activation of RhoA which mimics the physiological conditions of RhoA activation / inactivation cycles.
These properties make the peptides suitable for repeated administration and long term treatments. As the peptides only act on neurons and not on microglia or astrocytes, there is no risk for neuronal inflammation or glia scar formation.

IP Rights
PCT application in 2010
National applications in USA/Europe in 2011

Patent Owner
Charité – Universitätsmedizin Berlin
Hannover Medical School

Application Area:

Drug candidates for the treatment of neurodegenerative disorders

Development Stage: In vitro / in vivo

Tags: drug candi-date, Huntington cho-rea, Morbus Alzheimer, neurodegenerative disorders, Neuron-specific peptides, spinal cord injury, traumatic brain injury,

Further Categories: Life Science, Pharma & Biotech

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Benefits:

Physiological acting neuritogenic drug – small size and effective in nanomolar concentrations
Act neuron-specific -> reduced risk for neuronal inflammation or glia scar formation
Short peptides with low antigenicity and good kinetics
Broad application areas: Spinal cord injury, traumatic brain injury, Morbus Alzheimer, Parkinson, Huntington Chorea, etc.
In vivo data on spinal cord injury model show regenerative properties

Cytokinin Receptor Antagonists and Compositions Containing these Derivatives

08.12.2011 | Ref.Nr. 07114

Download as PDF PDF Download Share

Life Science › Nutrition

Generel formular of alylbenzylamino Picture: WO 2009/043320 A2 Background
Cytokinins are plant hormones involved in cell division, shoot meristem and leaf formation, chloroplast biogenesis, and senescence. The development of agonists and antagonists with a particular physiological effect is useful in mechanism-of-action studies of biologically active natural products. The potent naturally occurring cytokinin N6-isopentenyladenine served as the basis for initial structure-activity studies.

Technology
We offer substituted 6-(alkylbenzylamino)-purin derivatives as cytokinin receptor antagonists to provide cytokinin analogons for growth regulation in plants and to offer the possibility for a specific selectivity for cytokinin receptors without being toxic for animal cells. The derivatives can be used to influence morphology, leading to:

Increased root growth, fruit or grain size
Stimulation of root branching and enhanced number of lateral roots
Accelerated seed germination
Enhanced yield and quality of crops

IP Rights
Czech Patent Application was filed in 2007
PCT Patent Application was filed in 2008
National applications filed in USA and Europe

Patent Owner

Freie Universität Berlin
Palacky University Olomouc (CZ)

Application Area:

Applicable as plant growth regulator

Development Stage: Green house (plant model Arabidopsis thaliana)

Tags: 6-(alkylbenzylamino)-purin derivatives, cytokinin analogons, cytokinin receptor antagonist, Plant Growth Regulator, Purin Derivatives,

Further Categories: Life Science, Nutrition

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Agriculture industry

Benefits:

Non toxic for animal cells
Efficiency is proven in various test systems
Suitable regulator for proliferation and morphogenesis in tissue culture

Highly Efficient Light Emitters - The Route to Green Lasers

25.08.2011 | Ref.Nr. 06094

Download as PDF PDF Download Share

Physics&Engineering

Background
The emission of green laser light is of great importance for several applications and procedures in biology, medicine and multimedia. A powerful green laser could revolutionize the market for portable beamers. So far, semiconductor based light emitters, such as laser pointers, convert infrared light by frequency doubling into green light. A significant drawback of this technique is the loss of power and efficiency.

Technology
We offer green light emitting semiconductor devices including for example a green laser. The use of ZnCdO as a semiconductor material allows direct emission of green light without frequency doubling.

IP Rights
German Patent Application

Patent Owner

Humboldt-Universität zu Berlin, Germany

Application Area:

Green lasers, Laser diodes

Development Stage: Demonstrator

Tags: Green laser, Laser, laser technology, multimedia, semiconductor material,

Further Categories: Lasers, Semiconductor, Physics & Engineering

Licensing Manager: Dr. Kirk Haselton

T +49 30 2125 4842

F +49 30 2125 4822

kirk.haselton@ipal.de

Benefits:

Direct Green light emission (band gap 2.2 eV - 2.5 eV)
No frequency doubling involved
No loss of efficiency
High degree of crystalline perfection
High stable semiconductor material
Small, low cost device

Terahertz Quantum Cascade Lasers

25.08.2011 | Ref.Nr. 09018

Download as PDF PDF Download Share

Physics&Engineering

Background
Quantum Cascade Lasers (QCLs) are currently the best electrically-pumped sources of Terahertz (THz) radiation regarding output power, linewidth, operating temperatures and efficiency. THz QCLs offer a wide field of applications ranging from astrophysics and security screening to ultrafast spectroscopy in chemistry or biology. For all these applications THz QCLs which can operate at moderate temperature are desired.

Technology
The invention offers a THz Quantum Cascade Laser with improved temperature performance. The THz QCL uses a strain-compensated (Al, Ga, In)As material grown on InP substrates.

IP Rights
PCT Application

Patent Owner
Humboldt-Universität zu Berlin, Germany
University of Texas, USA